Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 16.7% increase over the number of companies inspected in the previous quarter, when six companies received six inspections.
Most of the companies inspected at the time were involved in the Biologics sector. The second most common type of company inspected worked in the Devices sector.
There were six companies in line with FDA regulations that do not need to adjust their management operations or regulatory/administrative actions. One should take voluntary action to correct its management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
| Company Name | Area of Business | Inspection Date | Result |
|---|---|---|---|
| Andersen Scientific, Inc. | Devices | 06/06/2024 | No Action Indicated (NAI) |
| Blood Connection, Inc. | Biologics | 05/02/2024 | No Action Indicated (NAI) |
| David S Huber Pipes | Tobacco | 05/30/2024 | No Action Indicated (NAI) |
| Duke University Medical Center Duke Hospital North | Biologics | 05/09/2024 | No Action Indicated (NAI) |
| Lalilab, Inc. | Food and Cosmetics | 05/15/2024 | No Action Indicated (NAI) |
| Suntech Medical, Inc. | Devices | 05/22/2024 | Voluntary Action Indicated (VAI) |
| Transfusion Medicine Service UNC Hospitals | Biologics | 05/24/2024 | No Action Indicated (NAI) |
Alerts Sign-up